Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial

The Lancet Infectious Diseases · Elsevier

Abstract

Publication date: October 2026 Source: The Lancet Infectious Diseases, Volume 26, Issue 10 Author(s): Rodney Dawson, Andreas H Diacon, Ebrahim Variava, Tumelo Moloantoa, William Brumskine, Tlhago Ngwanto, Ntokozo Zuma-Gwala, Ayman Osman, Mohammed Rassool, Jaclyn Ann Bennet, Yongge Liu, Raymond Xu, Wei Li, Simbarashe Takuva, Jeffrey Hafkin

Read at publisher →

Similar articles